The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 4, 2000, Pages 1518-1524

  Clemmons, David R ^a   Moses, Alan C ^d   McKay, Malcolm J ^b   Sommer, Andreas ^b   Rosen, David M ^b   Ruckle, John ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Celtrix Pharmaceuticals   (United States)

^c Northwest Kinetics   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FRUCTOSAMINE; GROWTH HORMONE; INSULIN; PLACEBO; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; TRIACYLGLYCEROL;

ADULT; ARTICLE; BELL PALSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; EDEMA; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA EDEMA;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; PLACEBOS;

EID: 0034456332     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.4.1518     Document Type: Article

References (37)

1. Characterization of insulin and somatomedin-C receptors in human placental cell membranes
2. Short-term metabolic effects of recombinant human insulin-like growth factor-I in healthy adults
3. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults
4. Acute effects of insulin-like growth factor-I on glucose and amino acid metabolism in the awake fasted rat
5. Effects of and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: Comparison with insulin
6. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes
7. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance
8. Treatment of type A insulin resistance with insulin-like growth factor I
9. Recombinant insulin like growth factor I (rh IGF-I) reduces hyperglycemia in patients with insulin resistance
10. Trial of insulin-like growth factor-I therapy for patients with extreme insulin resistance syndromes
11. Evidence from a dose ranging study that recombinant insulin-like growth factor-I (RhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus
12. rhIGF-I improves glucose control in insulin requiring type 2 diabetes
13. Dual hormonal replacement with insulin and insulin-like growth factor-I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile
14. RhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM
15. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type 1 diabetes mellitus
16. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans
17. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients
18. Effects of recombinant IGF-I and GH treatment upon serum IGF binding proteins in calorically restricted adults
19. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor-I by the use of both agents simultaneously
20. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I (IGF-I) in humans
21. Safety pharmacokinetics and biologic effects of intravenous administration of rhIGFI/IGFBP-3 to healthy subjects
22. Musculoskeletal effects of recombinant human insulin-like growth factor-I (rhigf-I)/IGF binding protein-3 (IGFBP-3) in hip fracture patients: Results from a double-blind, placebo-controlled, phase II study
23. IGF-I/IGFBP-3 complex ameliorates amino acid efflux and increases skeletal muscle protein synthesis in patients with severe burns
24. Benefit of systemically administered rh IGF-I and rh IGF-I/IGBP-3 on cancellous bone in oophorectomized rats
25. Actions of insulin-like growth factors
26. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects
27. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates
28. Potentiation of insulin like growth factor (IGF-I) activity by an antibody: Supportive evidence for enhancement of IGF-I bioavailability in vivo by IGF binding proteins
29. Inhibitory effects insulin-like growth factor binding proteins 1 and 3 on IGF activated glucose consumption in mouse Balb/c3T3 fibroblasts
30. Expression of human insulin-like growth factor-binding protein-3 in transgenic mice
31. Insulin-like growth factor binding protein-1 modulates blood glucose levels
32. Insulin like growth factor I improves glucose and lipid metabolism in type 2 diabetes mellitus
33. Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats
34. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone, and glucagon levels in young adults with insulin-dependent diabetes mellitus
35. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 insulin-dependent diabetes mellitus
36. Cotherapy with recombinant human insulin-like growth factor-I and insulin improves glycemic control in type 1 diabetes
37. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of non-insulin dependent diabetes mellitus subjects